Controlled-release Drug Delivery Technologies: Players, products & prospects to 2015

SUMMARY

This major strategic analysis provides a detailed insight into the current and future market for controlled-release drug delivery technology.

Providing...

Critical analyses and competitive ratings for major specialist developers Unique sales forecasts to 2015 for key current and new products utilising controlled-release drug delivery technologies A comprehensive examination of this major drug delivery sector

The controlled-release market is estimated to be worth over US$17 billion globally in 2007. Delivery specialists estimate that oral-dosage controlled-release delivery systems contribute the majority of sales around 90% and demonstrated +2% year-on-year growth.

By 2015, the report forecasts that controlled-release products in development from 22 key companies could generate additional sales of over US$11.7 billion. These products utilise a range of delivery platforms including diffusion, degradation and activated controlled-release systems. The world is likely to become a smarter place as site specific controlled-release technologies become a reality.

Opportunities now...

While the growth of controlled-release technology continues to be fuelled by line extensions helping to offset the impact of generic erosion this market is far from being exhausted. Many pharmaceutical companies have yet to make the additional investment to develop a controlled-release version of a product while the immediate-release version is under patent protection. Therefore, considerable market opportunities still exist in the development and application for precise, controlled-delivery products for both approved and new pharmaceuticals.

...and in the future

Controlled-release technologies are increasingly being applied in the preclinical development of products, leading to the parallel development of immediate-release and controlled-release formulations to maximise market exposure. Controlled-release formulations may potentially provide for greater effectiveness in the treatment of chronic conditions through more predictable kinetics; reduced side effects by minimising peak plasma concentrations; greater convenience and higher levels of patient compliance due to a simplified dosage schedule.

Answers to key questions

• What impact will companies such as Durect, OctoPlus, Penwest and Protherics have on the future competitive landscape?
• Can market leaders in controlled-release such as ALZA and Elan maintain their status in the face of growing competition?
• What are the relative strengths and weaknesses of the research pipeline?
• What strategies are proving most productive and for which companies?
• What will the product/company landscape look like in 2015?

TABLE OF CONTENTS

EXECUTIVE SUMMARY

• Competitor Ratio Analysis Summary

Introduction

Overview of controlled-re lease delivery : past , present & future

• Controlled-Release delivery: motivators & resistors
  • Motivators
  • Resistors
• Controlled-Release delivery: impact on product lifecycles

CONTROLED-RELEASE DELIVERY

• Types of controlled-release delivery used by pharma industry
  • Activated controlled-release delivery
    • Figure 1: Activated controlled-release delivery - ALZA's OROS systems
  • Degradation controlled-release delivery
    • Figure 2: Degradation controlled-release delivery - SkyePharma's GEOMATRIX
  • Diffusion controlled-release delivery
    • Figure 3: Monolithic diffusion controlled-release delivery - LaboPharm's Contramid
    • Figure 4: Reservoir diffusion controlled-release delivery - Impax' CMDS
    • Figure 5: Combined controlled-release delivery - Flamel's Micropump
    • Table 1: Advantages and disadvantages of controlled-release platforms
• Current therapeutic application of controlled-release in drug delivery
• Leading brands that utilise controlled-release delivery
  • Table 2: Controlled-Release approved drugs
• Future commercial applications & opportunities

STRATEGIES OF DRUG DELIVERY COMPANIES

• Leading controlled-release drug delivery companies
  • Table 3: Leading controlled-release drug delivery companies
• Partnerships & acquisitions
  • Strategic developmental & commercialisation partnerships
  • Merger & acquisitions
    • Table 4: Recent partnerships & acquisitions in the controlled-release field
• Intellectual Property
  • Table 5: Controlled-Release patents
• THE controlLed-release MARKET
  • Now 2007
    • Table 6: Approved controlled-release product sales
  • Future 2015
    • Table 7: Global controlled-release product sales
    • Table 8: Novel controlled-release product sales

COMPETITOR ANALYSIS

• Movers & Shakers: Cutting edge or losing their grip
  • Table 9: Movers & shakers in controlled-release drug delivery systems

COMPANY PROFILES

• AlphaRx Corporation
  • Table 10: AlphaRx' product pipeline
  • Table 11: AlphaRx' drug delivery sales
• ALZA Corporation
  • Table 12: ALZA's product pipeline
  • Table 13: ALZA's drug delivery sales
• Andrx Corporation
  • Table 14: Andrx' product pipeline
  • Table 15: Andrx' drug delivery sales
• Antares Pharma, Inc.
  • Table 16: Antares' product pipeline
  • Table 17: Antares' drug delivery sales
• Biovail International
  • Table 18: Biovail's product pipeline
  • Table 19: Biovail's drug delivery sales
• Camurus AB
  • Table 20: Camurus AB's product pipeline
  • Table 21: Camurus AB's drug delivery sales
• Cipher Pharmaceuticals, Inc.
  • Table 22: Cipher's product pipeline
  • Table 23: Cipher's drug delivery sales
• Debiopharm
  • Table 24: Debiopharm's product pipeline
  • Table 25: DebioPharm's drug delivery sales
• DelSite Biotechnologies, Inc.
  • Table 26: DelSite's product pipeline
• Depomed, Inc.
  • Table 27: Depomed's product pipeline
  • Table 28: Depomed's product sales
• Durect Corporation
  • Table 29: Durect's product pipeline
  • Table 30: Durect's product sales
• Eiffel Technologies
  • Table 31: Eiffel's product pipeline
• Elan Corporation
  • Table 32: Elan's product pipeline
  • Table 33: Elan's drug delivery sales
• Elite Pharmaceuticals, Inc.
  • Table 34: Elite's product pipeline
  • Table 35: Elite's product sales
• Endo Pharmaceuticals, Inc.
  • Table 36: Endo's product pipeline
  • Table 37: Endo's product sales
• Ethypharm SA
  • Table 38: Ethypharm's product pipeline
  • Table 39: Ethypharm's product sales
• Eurand
  • Table 40: Eurand's product pipeline
  • Table 41: Eurand's product sales
• Flamel Technologies, Inc.
  • Table 42: Flamel's product pipeline
  • Table 43: Flamel's product sales
• Glycologic, Ltd
  • Table 44: Glycologic's product pipeline
• Impax Laboratories, Inc.
  • Table 45: Impax' product pipeline
  • Table 46: Impax's product sales
• KV Pharmaceuticals, Inc
  • Table 47: KV's product pipeline
• Labopharm, Inc.
  • Table 48: Labopharm's product pipeline
  • Table 49: Labopharm's product sales
• Lavipharm SA
  • Table 50: Lavipharm's product pipeline
  • Table 51: Lavipharm's product sales
• OctoPlus N.V.
  • Table 52: Octoplus' product pipeline
  • Table 53: Octoplus' product sales
• Penwest Pharmaceuticals
  • Table 54: Penwest's product pipeline
  • Table 55: Penwest's product sales
• Protherics
  • Table 56: Protherics' product pipeline
  • Table 57: Protherics' drug delivery sales
• SCOL R Pharma, Inc.
  • Table 58: SCOLR's product pipeline
  • Table 59: SCOLR's drug delivery sales
• Shire
  • Table 60: Shire's product pipeline
  • Table 61: Shire's drug delivery sales
• Skinvisible, Inc.
  • Table 62: Skinvisible's product pipeline
• SkyePharma
  • Table 63: SkyePharma's CR product pipeline
  • Table 64: SkyePharma's controlled-release product sales
• Spherics
  • Table 65: Spheric's product pipeline

APPENDIX 1

• Table 66: Global controlled-release approved drugs sales 2006A-20015E

APPENDIX 2

• Table 67: Global controlled-release developmental drugs sales 2006A-20015E

APPENDIX 3

• Competitor Ratio Analysis Criteria
  • Table 68: Key Controlled-Release delivery companies by 2015

BIBLIOGRAPHY

GLOSSARY

ACRONYMS